The use of hydroxyurea before enrollment is permitted; hydroxyurea should be discontinued prior to start of study treatment; patients with symptoms/signs of hyperleukocytosis or white blood cell count (WBC) >,/uL can be treated with leukapheresis or may receive up to  dose of cytarabine (up to  mg/m^) anytime prior to enrollment
Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > ,/uL can be treated with leukapheresis or may receive up to  doses of cytarabine (up to  mg/m^/dose) prior to enrollment
The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > ,/uL can be treated with leukapheresis or may receive up to  doses of cytarabine (up to  mg/m^/dose) prior to study day  enrollment
The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > ,/uL can be treated with leukapheresis or may receive up to  doses of cytarabine (up to  mg/m^/dose) prior to enrollment
The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > ,/uL can be treated with leukapheresis or may receive up to  doses of cytarabine (up to  mg/m^/dose) prior to enrollment
Patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > ,/uL can be treated with leukapheresis prior to enrollment
Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > ,/uL can be treated with leukapheresis or may receive up to  doses of cytarabine (up to  mg/m^/dose) prior to enrollment